ReviewLife (Basel, Switzerland)2026
Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease and end-stage kidney disease worldwide, imposing a major clinical and economic burden. Conventional diagnostic markers, including albuminuria and estimated glomerular filtration rate (eGFR), have limited sensitivity and specificity for early disease detection and for accurately predicting progression. Increasing evidence suggests that DKD involves complex glomerular, tubular, inflammatory, fibrotic, and oxidative stress pathways that precede overt clinical manifestations. Consequently, considerable attention has focused on identifying novel noninvasive biomarkers, particularly urinary biomarkers, alongside selected circulating biomarkers and emerging multi-omics signatures. Proteins, peptides, extracellular vesicles, and RNA-based biomarkers have demonstrated promising diagnostic and prognostic potential for detecting early renal injury, improving risk stratification, and monitoring therapeutic response. This review summarizes recent advances in biomarker research for DKD, highlighting emerging molecular and omics-based signatures that may complement conventional markers in improving early detection, prognostic assessment, and disease phenotyping. While numerous biomarkers have shown promising associations with renal outcomes and disease progression, the majority remain investigational. Their translation into routine clinical practice will depend on rigorous external validation, standardized analytical methods, and demonstration of added value beyond established clinical measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.